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Abstract
Multiple Myeloma (MM) is a B-cell malignancy that is characterized by osteolytic bone lesions. It has been postulated that
positive feedback loops in the interactions between MM cells and the bone microenvironment form reinforcing ‘vicious
cycles’, resulting in more bone resorption and MM cell population growth in the bone microenvironment. Despite many
identified MM-bone interactions, the combined effect of these interactions and their relative importance are unknown. In
this paper, we develop a computational model of MM-bone interactions and clarify whether the intercellular signaling
mechanisms implemented in this model appropriately drive MM disease progression. This new computational model is
based on the previous bone remodeling model of Pivonka et al. [1], and explicitly considers IL-6 and MM-BMSC (bone
marrow stromal cell) adhesion related pathways, leading to formation of two positive feedback cycles in this model. The
progression of MM disease is simulated numerically, from normal bone physiology to a well established MM disease state.
Our simulations are consistent with known behaviors and data reported for both normal bone physiology and for MM
disease. The model results suggest that the two positive feedback cycles identified for this model are sufficient to jointly
drive the MM disease progression. Furthermore, quantitative analysis performed on the two positive feedback cycles
clarifies the relative importance of the two positive feedback cycles, and identifies the dominant processes that govern the
behavior of the two positive feedback cycles. Using our proposed quantitative criteria, we identify which of the positive
feedback cycles in this model may be considered to be ‘vicious cycles’. Finally, key points at which to block the positive
feedback cycles in MM-bone interactions are identified, suggesting potential drug targets.
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Introduction
Multiple Myeloma (MM) is a B-cell malignancy associated with
high morbidity and short survival duration post-diagnosis. 60–
70% of MM patients have bone involvement at the time of
diagnosis (60% of them with bone pain and 25% of them with
bone fracture), and 90% of MM patients will develop bone lesions
during the course of the disease [2–5]. MM can be associated with
a systematic thinning of bone or with the formation of focal
osteolytic lesions [6]. The bone lesions result in osteopenia and
pathologic fractures (i.e., compression fractures of the spine),
which significantly impact on patient morbidity, performance
status (including immobility, loss of independence and loss of
dignity) and survival duration [3].
Bone is a dynamic tissue that undergoes remodeling in adults,
periodically being resorbed by osteoclasts followed by new bone
formation by osteoblasts. Coordinated coupling between osteoclast
and osteoblast activity is necessary to maintain the balance be-
tween bone resorption and bone formation in adults [7,8]. How-
ever, coordination between osteoclasts and osteoblasts is dysreg-
ulated in several disease, such as osteoporosis [9] and Paget’s
disease [10], resulting in an imbalance between bone resorption
and bone formation.
In patients with MM, the imbalance between bone resorption
and formation occurs through increased osteoclast activity and
a lesser increase in osteoblast activity, leading to net bone
destruction [5]. The bone loss is often focal and significant, and
may lead to the collapse of vertebrae or the breakage of long
bones. MM cells cause bone loss through simultaneously
promoting osteoclast activity and inhibiting osteoblast activity by
secreting various soluble growth factors and cytokines, and by
modifying cell-cell adhesion. In addition, growth factors released
by bone resorption together with altered cell-cell adhesion
facilitate the proliferation of MM cells [5,11]. It has been
postulated that positive feedback loops in the interactions between
MM cells and the bone microenvironment form reinforcing
‘vicious cycle(s)’ [12,13], resulting in elevated bone resorption,
which in turn, is then coupled with enhanced MM cell population
growth in the bone marrow cavity.
Within the past two decades, a number of prospective
components and interactions involved in MM-bone positive
feedback cycles have been identified through experiments. Based
on these experimental observations, much effort has been made by
biologists to integrate the known components and interactions,
leading to a few candidate conceptual models of MM-bone positive
feedback cycles [5,14–16]. Despite advances in a systematic
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representation of MM-bone interactions, the dynamics of these
interactions and their relative importance are unknown. The issues
can be addressed by computational modeling, as it can provide
systematic and quantitative insights into MM-bone feedback loops
and the way these cycles may interact to cause bone destruction.
The computational modeling of MM-bone interactions involves
trade-offs. While a more complete model may be more accurate,
waiting until everything is known about the system is not practical.
On the other hand, including everything that is currently known
may lead to a computational model that is impractical because
many unmeasured parameters would have to be estimated.
Further, the additional model complexity may result in little gain
in understanding. A balance is required between model simplicity
and complexity to develop a realistic model that can help address
significant questions as to the origin and management of MM-
induced osteolysis. Here a key question arises: can the most
important mechanisms identified by biologists appropriately drive
and explain the MM disease evolution? In terms of a new and
tentative computational model of MM-induced osteolysis, it is
clearly desirable to include only the most important mechanisms in
MM-induced osteolysis.
In comparison to the growing numbers of components and
interactions identified by biologists to date, there has been very little
investigation of the dynamics of the interplays of these interactions
by mathematical/computational modelers. To our knowledge,
Ayati et al. [17] recently developed the only mathematical model
investigating the dynamics of the MM-bone vicious cycle. In the
case of untreated MM, the mathematical model appears to capture
some qualitative features of MM disease progress (i.e., an increase in
MM-cell density and a decrease in bone volume) in basic multi-
cellular units (BMUs) of trabecular bone. However, molecular based
cell-cell signaling pathways have not been explicitly modeled, but
rather are abstracted into three phenomenological pathways (MM
cells inhibit osteoblasts, MM cells increase osteoclasts and bone
resorption stimulates tumor growth). For this reason, there is no
clear connection between model parameters and the bone
physiology (or the MM pathology).
In this paper, we develop a computational model involving
feedback cycles between MM and bone cells, and clarify whether
the most important cell-cell signaling implemented in this model
appropriately drive MM disease progression. The interactions
between MM cells and the bone microenvironment have to be
properly represented in the model, and then the dynamics of the
MM-bone interactions have to be investigated to test whether this
model captures major features of MM disease progression.
Consequently, two most important tasks are required to develop
a suitable model of MM-bone interactions: (i) selecting the most
important mechanisms driving MM disease progression; and (ii)
parameterizing these mechanisms using chemical and physical
model principles informed by biological data. At the same time
the proposed computational model is to be kept as simple as
possible.
This computational model is based on a previous computational
model of bone remodeling (in the absence of MM cells) developed
by Pivonka et al. [1,18]. While Pivonka et al. ’s model [1] already
explicitly considers several regulatory factors together with bone
cells to describe the couplings between bone resorption and bone
formation, further bone regulatory factors believed to be dysregu-
lated during MM disease progression need to be incorporated into
this bone model. By explicitly considering interleukin-6 (IL-6) and
multiple myeloma-bone marrow stromal cell (MM-BMSC) adhe-
sion related pathways, a new tentative MM-bone model is
developed, and two positive feedback cycles in MM-bone inter-
actions can then be identified in this model. TheMM-bone model is
a system of ordinary differential equations (ODEs) that are solved by
numerical integration. The parameters of this model are estimated
based on reported values in the literature, and when required, from
best-fit parameter estimates from a least-square optimization
criterion. The dynamics of MM and bone cells predicted by this
model are in accord with biological and clinical observations, both
in the normal and disease states. The qualitative and quantitative
comparison of dynamic simulations with features of the MM disease
progression (i.e., increase in the density of bone cells, in the density
of MM cells, and in the concentrations of IL-6 and receptor
activator of nuclear factor-kB ligand (RANKL), together with
decrease in the concentration of osteoprotegerin (OPG), and
decrease in the bone volume) shows that the proposed computa-
tional model appropriately reflects MM disease progression. In
particular, two positive feedback cycles identified in the computa-
tional model are sufficient to jointly drive MM disease progression.
With two positive feedback cycles identified, the relative
importance of each cycle is not completely clear. While the
terminology ‘vicious cycle’ is commonly used in the biological/
cancer literature to identify positive feedback loops between the
cancer cells and their microenvironment, it is not usually given a
quantitative definition. In this paper, quantitative analysis is
performed based on comparing total changes of MM-cell density
and bone volume over time, when both positive feedback cycles
are intact and when either one or the other, or both, of the positive
feedback cycles are disabled (i.e., blocked). Using our proposed
quantitative criteria, the relative contribution of the two positive
feedback cycles is clarified and ‘vicious cycles’ identified.
Furthermore, our analysis identifies key regulation molecules that
if blocked, would inhibit the positive feedback cycles in MM-bone
interactions, thereby suggesting possible drug targets appropriate
for either the alleviation of MM-tumor burden or the improve-
ment in MM-induced bone lesions.
The paper is organized as follows. In Section Methods, the
MM-bone model structure is described. In Section Results, the
governing equations of the (MM-free) bone model and MM-bone
model are developed. The progression of MM disease is simulated
numerically from normal bone physiology in the absence of MM
cells to a well established MM disease state in the presence of MM
cells. Simulations are qualitatively and quantitatively compared
with clinical observations for normal bone physiology and for MM
disease. In Section Discussion, quantitative analysis is performed
on the positive feedback cycles that are identified and validated in
the MM-bone model.
Methods
2.1 The structure of the MM-bone model
Before positive feedback cycles in the interactions between MM
cells and the bone microenvironment can be investigated, the
bone microenvironment has to be well understood, as it is a
complex system in its own right. Two bone homeostasis models
[1,19], which incorporate parathyroid hormone (PTH), RANKL/
OPG/RANK pathway and transforming growth factor b (TGF-b)
regulatory couplings between the osteoblast lineage cells and
osteoclast lineage cells, were proposed to drive the dynamics of
bone cells through the underlying molecular mechanisms. For the
model perturbations investigated in Lemaire et al. [19] (e.g.,
adding external bone cells into the bone model), there is
qualitative agreement between experimental and clinical obser-
vations, suggesting that the molecular mechanisms included in the
model capture key couplings between the osteoblastic lineage and
the osteoclastic lineage. Because the Pivonka et al. model [1] is
derived from the Lemaire et al. model [19], the two bone models
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are similar in their behavior. However, one important difference
is that while it is assumed that OPG is secreted from osteoblast
precursors and RANKL is expressed on active osteoblasts in
Lemaire et al. [19], in Pivonka et al. [1] these assumptions are
reversed (i.e., RANKL is expressed on osteoblast precursors and
OPG is secreted by active osteoblasts). There is extensive
biological evidence that supports the Pivonka et al. model [1],
and it clearly makes sense at the level of the BMU [20]. As a
result, our attempt to model MM-bone interactions is based on
the bone model of Pivonka et al. [1].
Figure 1 illustrates the structure of this bone model, and the
interactions between cells of the osteoblastic lineage and osteo-
clastic lineage are highlighted by regulation mechanisms 1, 2 and
3. As described in Table 1, PTH stimulates RANKL expression on
the surface of osteoblast precursor cells (OBp) while PTH inhibits
OPG secretion by active osteoblasts (OBa). RANKL binds to
receptor activator of nuclear factor-kB (RANK) on the surface
of osteoclast precursors (OCp) triggering the differentiation of
osteoclast precursors into active osteoclasts (OCa), which is
inhibited by OPG due to its competitive binding to RANKL.
The relative RANKL and OPG concentration controls osteoclast
differentiation and number. In addition, active osteoclasts resorb
bone leading to TGF-b being released into the bone microenvi-
ronment. The released TGF-b has various actions, including
stimulating the differentiation of uncommitted osteoblasts (OBu),
inhibiting the differentiation of osteoblast precursors and facilitat-
ing the apoptosis of active osteoclasts.
Taking the bone cell population model of Pivonka et al. [1], we
first extend this bone model by incorporating regulatory factors
that are important for MM in the context of the bone micro-
Figure 1. Schematic of the MM-bone model structure. Regulation mechanism 1: PTH stimulates RANKL expression on the surface of osteoblast
precursors while inhibiting OPG secretion by active osteoblasts. Regulation mechanism 2: RANKL binds to RANK, which promotes the differentiation
of osteoclast precursors, while OPG inhibits the RANKL-RANK binding. Regulation mechanism 3: Bone resorption released TGF-b stimulates
uncommitted-osteoblast differentiation, inhibits osteoblast-precursor differentiation and facilitates the apoptosis of active osteoclasts. Regulation
mechanism 4: MM cells adhere to BMSC, enabling IL-6 secretion by BMSC, RANKL expression on the surface of BMSC and MM-cell proliferation.
Regulation mechanism 5: IL-6 facilitates MM-cell proliferation and stimulates RANKL expression on the surface of osteoblast precursors. Regulation
mechanism 6: bone resorption released TGF-b stimulates IL-6 production by BMSC. Regulation mechanism 7: OPG is internalized and degraded by
MM cells.
doi:10.1371/journal.pone.0027494.g001
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environment (see Section 3.1.1), and further develop the extended
bone model by incorporating MM cells and the most important
intercellular interactions between MM cells and the bone micro-
environment (see Section 3.2.1). Figure 1 illustrates the proposed
structure of the MM-bone model. The interactions between MM
cells and bone cells are highlighted by regulation mechanisms 4, 5,
6 and 7. These are briefly described in Table 1. Each mechanism
and its biological justification are now discussed in turn.
Bone marrow stromal cells (BMSC) are considered as early
progenitors derived from mesenchymal stem cells (MSC) and
have potential to commit to various mesenchymal cell lineages
(including the osteoblast cell lineage) [21,22]. Accordingly, BMSCs
are modeled as uncommitted osteoblasts (OBu) rather than
osteoblast precursors (OBp) in the MM-bone model. Several
known conceptual models [14,15] indicate that MM cells adhere
to BMSCs mediated by the adhesion molecules such as very-late
antigen 4 (VLA-4) expressed on the surface of MM cells, and
vascular cell adhesion molecule 1 (VCAM-1) expressed on the
surface of BMSCs. The MM-BMSC adhesion appears to play a
number of important roles in MM-bone positive feedback cycles.
For example, MM-BMSC adhesion induces MM-cell proliferation
through activation of phosphatidylinositol 3-kinase (PI-3K),
mitogen-activated protein kinase (MAPK) and nuclear factor-kB
(NF-kB) pathways in MM cells [14,23]. Importantly, NF-kB
activation in BMSC induces increased production of IL-6 by
BMSCs [14]. Furthermore, MM-BMSC adhesion increases
production of RANKL by BMSCs [14]. All these aspects are
captured in the MM-bone model and are highlighted in the
diagram by regulation mechanism 4.
IL-6 is an ‘osteoclastogenic factor’ that in the bone microen-
vironment is only produced by cells of the osteoblastic lineage
[24,25]. TGF-b released from the bone matrix during resorption,
also stimulates IL-6 secretion by BMSCs through the activation
of NF-kB pathway [14,26]. IL-6 in turn stimulates RANKL
production by osteoblast precursors through the STAT3-depen-
dent pathway (while PTH stimulates RANKL production through
the PKA pathway) [27]. The IL-6 concentrations are usually small
in the normal bone microenvironment, and so are thought not to
exert significant effects on osteoclast activity under conditions of
normal bone physiology [28–30]. However in patients with MM,
IL-6 does become significant in the regulation of bone cells [31].
IL-6 is produced in significant quantities by BMSCs in response
to MM-BMSC adhesion and activation of the NF-kB sig-
naling pathway [14,32–34]. More specifically, both TGF-b and
MM-BMSC adhesion regulate IL-6 secretion by BMSC, and the
effect on both regulatory pathways is synergistic [35], leading to
substantially increased IL-6 concentrations in the context of MM.
IL-6 is also known to be one of the most important factors
stimulating MM-cell proliferation [23]. IL-6 stimulates (via the
triple complex IL-6/gp130/IL-6R) the activation of PI-3K,
MAPK and NF-kB signaling pathways, which allow MM cells to
proliferate and resist the induction of apoptosis by conventional
therapeutics such as dexamethasone [23]. It is noted that these
down-stream signaling pathways are also triggered by the MM-
BMSC adhesion complex [14,36,37]. The roles of IL-6 on MM-
cell proliferation and osteoclast activity, as well as production of
IL-6 in patients with MM, are highlighted in the diagram by
regulation mechanisms 5 and 6 respectively.
Osteoclast activity is directly controlled by the RANKL/OPG/
RANK pathway. Further RANKL is produced by osteoblast
precursors in response to PTH and IL-6 stimulation [27].
Additional RANKL is produced by BMSCs in response to MM-
BMSC adhesion [14]. On the other hand, OPG is internalized
and degraded by MM cells [38], tending to reduced local OPG
concentrations. The increase in RANKL and decrease in OPG
leads to an elevated RANKL/OPG ratio and so increased
osteoclast activation. This is highlighted in the diagram by
regulation mechanisms 4 and 7 respectively.
MM cells are eliminated too. For example, the apoptosis of MM
cells occurs due to the actions of T cells [39,40], but this apoptosis
may be inhibited by the action of TGF-b on T cells [41].
However, for the purpose of simplifying our model, the apoptosis
rate of MM cells is assumed constant. More detailed regulations of
anti-apoptosis of MM cells will be considered in future models.
In addition to IL-6, other soluble factors also contribute to MM-
cell population growth and increased bone resorption although
their contributions appear to be less than those of IL-6. For
example insulin-like growth factor 1 (IGF-1), which is released
from the bone matrix during bone resorption, stimulates MM-cell
proliferation and survival [23]. Vascular endothelial growth factor
(VEGF) is produced by MM cells and stimulates the growth of
blood vessels which supports MM cell growth [42], leading to a
positive autocrine feedback loop. Macrophage inflammatory
protein-1a (MIP-1a) is secreted by MM cells [43] and activates
VLA-4 on the surface of MM cells, which enhances MM-BMSC
adhesion mediated by VCAM-1 binding to VLA-4 binding
[44,45]. The enhanced MM-BMSC adhesion stimulates IL-6
and RANKL production by BMSCs, suggesting that MIP-1a
Table 1. The Description of regulation mechanisms involved in the MM-bone model.
models Mechanisms description
Bone model Regulation mechanism 1 PTH stimulates RANKL expression on the surface of osteoblast precursors, while inhibiting OPG secretion by active
osteoblasts.
Regulation mechanism 2 RANKL binds to RANK, which promotes osteoclast precursor differentiation, while OPG inhibits RANKL-RANK
binding.
Regulation mechanism 3 Bone resorption released TGF-b stimulates uncommitted-osteoblast differentiation, inhibits osteoblast-precursor
differentiation and facilitates apoptosis of active osteoclasts.
MM-bone model Regulation mechanism 4 Adhesion of MM cells to BMSC induces the proliferation of MM cells, production of IL-6 by BMSC and expression of
RANKL on the surface of BMSC.
Regulation mechanism 5 IL-6 facilitates MM-cell proliferation and RANKL expression on the surface of osteoblast precursors.
Regulation mechanism 6 Bone resorption released TGF-b stimulates IL-6 production by BMSC.
Regulation mechanism 7 OPG is internalized and degraded by MM cells.
doi:10.1371/journal.pone.0027494.t001
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increases bone resorption by RANKL-mediated pathways [5].
The enhanced MM-BMSC adhesion also induces MM cell
proliferation due to increased IL-6 concentrations, which in turn
promotes secretion of MIP-1a by MM cells and forms a positive
feedback cycle [46]. Given our goal for creating a simple
computational model by incorporating representative known factors
rather than all known factors, in this computational model all these
soluble factors (including IGF-1, VEGF and MIP-1a) are
considered to have much smaller effects on MM-cell prolifera-
tion than those triggered by IL-6. We acknowledge that this
assumption is a potential shortcoming of this computational
model.
In patients with MM, it has also been proposed that Wnt
signaling is blocked by Dickkopf-1 (DKK-1) [47] and by secreted
frizzled-related protein-2 (sFRP-2) [48], which are both secreted
by MM cells [49,50], leading to the inhibition of bone formation
in MM disease. However, the precise mechanisms by which
DKK-1 and sFRP-2 regulate the osteoblast functions remain to
be determined [6,12]. In the MM-bone model presented here we
do not incorporate these poorly understood mechanisms. We
acknowledge that this assumption might be another shortcoming
of the computational model. Mechanisms associated with
inhibition of MM cells on bone formation will be considered in
future models.
Taken together, all the regulation mechanisms in this model are
found to form two positive feedback cycles. As Figure 2 shows, IL-
6 secreted by BMSCs induces increased RANKL expression on
osteoblast precursors, leading to bone resorption. TGF-b released
during bone resorption, in turn, stimulates the secretion of IL-6 by
BMSCs. This ‘positive feedback loop’ forms a positive feedback
cycle within the bone microenvironment (identified as cycle A in
Figure 2), which is enhanced by the increased IL-6 concentrations
due to MM-BMSC adhesion stimulation. This cycle does not
normally have a significant effect on bone resorption, because
TGF-b acting alone only stimulates a small increase in IL-6
secretion by BMSCs in the context of normal bone physiology.
However, in the presence of MM cells and with the simultaneous
stimulation of TGF-b and MM-BMSC adhesion, a substantial
increase in IL-6 secretion by BMSCs occurs. The elevated IL-6
concentrations now contribute to the positive feedback cycle,
producing significant impacts on bone resorption.
On the other hand, IL-6 and MM-BMSC adhesion stimulate
MM-cell proliferation, which in turn promotes IL-6 production
by BMSC and enhances MM-BMSC adhesion. This leads to
another ‘positive feedback loop’, so forming a second cycle
between MM cells and the bone microenvironment (identified as
cycle B in Figure 2). Due to the dual roles played by IL-6 in these
positive feedback cycles (both an osteoclastogenesis factor and a
stimulatory factor of MM-cell proliferation), the first and the
second cycles interact with each other, enhancing IL-6 produc-
tion. This induces a positive feedback cycle between MM cells
and the bone microenvironment triggered by either TGF-b or
MM-BMSC adhesion. Two additional signaling pathways, MM-
BMSC adhesion stimulating RANKL expression on the surface of
BMSCs (identified as pathway C in Figure 2), and MM-cells
degrading OPG (identified as pathway D in Figure 2), also
serve to enhance the positive feedback cycles between MM cells
and the bone microenvironment by increasing the RANKL/
OPG ratio.
2.2 Cellular response to simultaneous stimulation by two
ligands
In the bone remodeling model of Pivonka et al. [1], cell-cell
regulatory communication is represented by chemical mass-action
equations, while cellular process are represented by transfer
functions, usually Hill functions of the form:
pact~
L
LzKM1
, ligand activates cell behavior ð1Þ
prep~
KM2
LzKM2
, ligand represses cell behavior ð2Þ
where pact and prep represent the ‘activator’ or ‘repressor’ func-
tion respectively; L is the ligand concentration; and KM1 and
KM2 represent the half-maximal concentrations respectively, which
are the ligand concentrations inducing a half-maximal cell
response.
In the proposed MM-bone model, three cases of cellular
processes are simultaneously controlled by two ligands (rather than
by a single ligand): (i) RANKL production by osteoblast precursors
is co-regulated by PTH and IL-6, (ii) MM-cell proliferation is co-
regulated by MM-BMSC adhesion and IL-6; and (iii) IL-6
production by BMSC is co-regulated by TGF-b and MM-BMSC
adhesion. Accordingly, equations (2) and (3) (used in the Pivonka
et al bone model [1]) need to be extended to appropriately model
the cellular process in response to stimulation by two ligands (L1
and L2).
The feature of simultaneous stimulation by two ligands is that
there may exist intracellular interactions between the two separate
ligand signaling pathways, which induce nonlinear cellular
outputs. For our current needs, the intracellular interaction may
induce an ‘enhanced’ cellular response (that is, a response that is
greater than the cellular response to one ligand stimulation alone,
but lower than the sum of cellular responses to each ligand
stimulation acting separately), or a ‘synergistic’ cellular response
(that is, a response that is greater than the sum of cellular
responses to each ligand stimulation acting separately). For the
intermediate case, the intracellular interaction may induce an
‘additive’ cellular response (that is, a response that is exactly equal
to the sum of cellular responses to each ligand stimulation acting
separately). The biological evidence indicates that RANKL
production by osteoblast precursors is ‘enhanced’ under co-
regulation by PTH and IL-6 [27], and that MM-cell proliferation
is also ‘enhanced’ under co-regulation by MM-BMSC adhesion
and IL-6 [23]; while IL-6 production by BMSC is ‘synergistic’
under co-regulation by TGF-b and MM-BMSC adhesion because
the ratio of IL-6 production by two ligands stimulation compared
to the sum of each ligand separately is between 1.45-fold and 2-
fold [35].
Given the above description of the observed behaviors,
mathematically, we define a response function f (L1,L2) which
meets the following constraints:
N There is at least a nonlinear term in the definition of the
transfer function to reflect non-linear intracellular interactions
between the two inputs.
N For the ‘enhanced’ response, the response function f is greater
than either p1 and p2 but lower than the sum of p1 and p2 (i.e. f
. p1 and f . p2 but f , p1+p2), while for the synergistic
response, the response function f . p1+ p2.
The following function meets the above constraints (and has
been successfully applied in modeling gene regulatory motifs [51]
and synergistic effects of two inhibitors respectively [52], and so is
a candidate response function to model cellular responses when
there is stimulation by two ligands:
Modelling of Multiple Myeloma-Bone Interactions
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f (L1,L2)~p1zp2zc:p1:p2,
p1~
L1
L1zKM1
,p2~
L2
L2zKM2
{1ƒcv0, for 0enhanced0 reponse
c~0, for 0additive0 response
cw0, for 0synergistic0 response
ð3Þ
where p1 and p2 represents the ‘activator’ function for each ligand,
L1 or L2 (although we take the ‘activator’ function for example in
here it should be noted that p1 and p2 can also represent the
‘repressor’ function for each ligand L1 or L2), L1 and L2 are the
ligand concentration respectively, and KM1 and KM2 are the half-
maximal concentrations. c is a parameter that may be calibrated
to reflect the enhanced, the additive, or the synergistic effects that
are observed experimentally.
Figure 3 illustrates the functional dependence of f on L1 and L2
concentrations. To meet the functional requirements described
above, c has to be greater than or equal to -1. For c . -1, the
function f increases with increase in L1 and L2 concentration, and
the rate of change of f to an increase in ligand is more rapid with
an increasing c value. We choose c to be -1 for the enhanced two-
ligand interactions for simplicity, and c is calibrated to be about 25
for the synergistic response. As demonstrated below, simulations
using these parameter values appear to be in good agreement with
observations for IL-6 and RANKL in normal bone physiology,
and as demonstrated later, there is also good agreement at the
various stages of MM disease.
Results
3.1 Bone model in the absence of MM cells
In the absence of MM cells, several behaviors of normal bone
physiology have been shown to be captured by the bone
remodeling model of Pivonka et al. [1,18]. However, to include
the interactions between MM cells and bone cells adequately, this
bone remodeling model needs to be extended to incorporate the
mechanisms of TGF-b-stimulated IL-6 production by BMSC and
IL-6-stimulated RANKL expression on the surface of osteoblast
precursors. The newly introduced IL-6 should not significantly
change the original behaviors between osteoclast and osteoblast
functions as captured in the model of Pivonka et al. [1,18] under
Figure 2. Schematic of the positive feedback cycles in the MM-bone model. The positive feedback loop A forms the first cycle within the
bone microenvironment, which is enhanced by the increased IL-6 concentrations due to MM-BMSC adhesion. IL-6 secreted by BMSC stimulates
elevated RANKL expression on the surface of osteoblast precursors and further increased active osteoclasts, leading to bone resorption and TGF-b
released from bone resorption. Released TGF-b, in turn, stimulates more IL-6 secretion by BMSC. The positive feedback loop B forms the second cycle.
Simultaneous stimulation of MM-BMSC adhesion and TGF-b induces substantial IL-6 secretion by BMSC, which (together with MM-BMSC adhesion)
causes MM-cell proliferation and further enhanced MM-BMSC adhesion. The first and the second cycle interact with each other by enhancing IL-6
production. Two regulations, MM-BMSC adhesion stimulating RANKL expression on the surface of BMSC and MM-cell degrading OPG, enhance the
positive feedback cycles of MM-bone interactions through increasing IL-6 concentrations.
doi:10.1371/journal.pone.0027494.g002
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normal bone conditions, as this has been extensively validated.
Consequently, the IL-6 related parameters need to be carefully
estimated, allowing that IL-6 produces insignificant impacts on the
normal bone physiology, but does produce significant effects in the
MM disease state.
In this next section, we present in detail how IL-6-related
mechanisms are incorporated into the previous Pivonka et al. [1]
model and demonstrate that our extended (MM-free) bone model
correctly retains the osteoclast and osteoblast behaviors as occurs
in the original model of Pivonka et al. [1,18]. The calibration of
the new extended bone model is made to quantitatively reflect the
known minor IL-6 role(s) in normal bone physiology.
3.1.1 Formulation of governing equations. According to
the bone model of Pivonka et al. [1] the dynamic equations of
describing bone cell populations are as follows:
dOBp
dt
~DOBu
:OBu:p
TGFb
act,OBu
{DOBp
:OBp:p
TGFb
rep,OBp
ð4Þ
dOBa
dt
~DOBp
:OBp:p
TGFb
rep,OBp
{AOBa
:OBa ð5Þ
dOCa
dt
~DOCp
:OCp:p
RANKL
act,OCp
{AOCa
:OCa:p
TGFb
act,OCa
ð6Þ
where, OBu, OBp, OBa, OCp and OCa represent uncommitted
osteoblasts, osteoblast precursors, active osteoblasts, osteoclast
precursors and active osteoclasts respectively. DOBu, DOBp and DOCp
represent the differentiation of OBu, OBp and OCp respectively.
AOBa and AOCa represent the apoptosis of OBa and OCa
respectively. pTGFbact,OBu , p
TGFb
act,OCa
and pRANKLact,OCp represent ‘activator’
functions while pTGFbrep,OBp represents a ‘repressor’ function. These
‘activator’ and ‘repressor’ functions are defined by the Eq.(1) and
(2) respectively and are the same as those in the model of Pivonka
et al. [1].
Changes over time in the active osteoblast and osteoclast
populations relative to each other, result in changes in bone
volume, which is a ‘system output’ of the bone model. The
calculation of bone volume is the same to that in Pivonka et al.
[18]:
dBV
dt
~{kres:OCazkform:OBa ð7Þ
where BV represents normalized bone volume, kres and kform
represents relative rate of bone resorption and bone formation
respectively with the unit of %:pM{1:day{1.
In the extended bone model IL-6 production by BMSC/OBus is
stimulated by TGF-b. The dynamic equation describing IL-6
concentration is as follows:
dIL6
dt
~PIL6,dzbIL6
:OBu:p
TGFb
act,IL6
:(1{
IL6
IL6max
){DIL6:IL6 ð8Þ
The molecular concentration changes and molecular reactions
occur much faster than cellular changes, and as a result of this
Figure 3. Functional dependence of f on L1 and L2 concentrations (c= -2, -1, 0, and 10 respectively, KM1=2 and KM2=3).
doi:10.1371/journal.pone.0027494.g003
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separation of time scales, it is appropriate to assume that molecules
and receptors are always at equilibrium. The quasi-steady state
concentration of IL-6 is solved from Eq.(8) as follows:
IL6~
PIL6,dzbIL6
:OBu:p
TGFb
act,IL6
bIL6
:OBu:p
TGFb
act,IL6
IL6max
zDIL6
ð9Þ
pTGFbact,IL6~
TGFb
TGFbzKM,TGFb,IL6,act
ð10Þ
where, PIL6,d is the external production rate of IL-6 with the unit of
pM:day{1. bIL6 is the endogenous production of IL-6 by OBu
with the unit of day{1. IL6max is the maximum concentration of
IL-6. DIL6 is the degradation of IL-6. p
TGFb
act,IL6 is the ‘activator’
function and KM,TGFb,IL6,act is the half-maximal concentration of
TGF-b promoting the production of IL-6.
RANKL production is controlled by both PTH and IL-6 in the
extended bone model, and so the calculation of RANKL
concentration at the steady state is updated from the Pivonka et
al. model [1] as follows:
RANKLeff~R
RANKL:OBp:p
ligands
RANKL ð11Þ
pligandsRANKL~p
IL6
act,RANKLzp
PTH
act,RANKL{p
IL6
act,RANKL
:pPTHact,RANKL ð12Þ
pIL6act,RANKL~
IL6
IL6zKM,IL6,RANKL,act
ð13Þ
RANKL~
PRANKL,dzbRANKL
:OBp
(1zKA,OPG:OPGzKA,RANK :RANK):(
bRANKL
RRANKL:pligandsRANKL
zDRANKL)
ð14Þ
where RANKLeff represents the ‘effective carrying capacity’ on the
surface of osteoblast precursors, which is the maximum concen-
tration of RANKL. KA,OPG and KA,RANK are the association rate
constant for RANKL binding to OPG and RANK respectively.
RRANKL is the maximal number of RANKL that can be expressed
on the surface of osteoblast precursors. PRANKL,d is the external
production rate of RANKL with the unit of pM:day{1. bRANKL is
the endogenous production of RANKL by each OBp cell with the
unit of day{1. DRANKL is the degradation of RANKL. p
ligands
RANKL is
the enhanced (c~{1) ‘activator’ function in response to
simultaneous PTH and IL-6 stimulation (see discussion for
Eq.(3)). pIL6act,RANKL and p
PTH
act,RANKL are the single ‘activator’
functions in response to PTH and IL-6 stimulation. KM,IL6,RANKL,act
is the half-maximal concentration of IL-6 on promoting the
production of RANKL.
The calculations of concentrations of TGF-b, PTH and OPG
are the same as described in Pivonka et al. [1] (see Supporting
Information S1).
3.1.2 Perturbations on bone model. Before perturbations
are performed to test the behavior of the extended bone model,
this model has to reach the steady state representing normal bone
physiology. To do this, the density of bone cells at steady state are
re-estimated here based on reported values for adults available in
the literature (see Table 2), and so are different to the bone-cell
densities used by Pivonka et al. [1,18]. The parameter values of the
extended bone model are carefully estimated so that re-estimated
bone-cell densities (see Table 2) are obtained when solved using
the routine ‘fsolve’ in the Matlab (see parameter estimates in
Table 3).
After this calibration, various perturbations of this model are
performed from steady state (by adding or removing cells or
signaling molecules) and the effects of the perturbations are
compared with the responses obtained in Pivonka et al. [1,18].
This allows us to clarify whether this extended bone model is able
to keep the original changes in density of bone cells and keep the
original changes in bone volume (as reported in the Pivonka et al.
model [1,18]). Perturbed cells or signaling molecules are expected
to quickly reach a new steady state and to quickly recover to the
original steady state when perturbations are removed, just as they
did in the Pivonka et al. model [1,18]. In the series of tests, all the
perturbations are added at day 20 and end at day 80 (after the
extended bone model has reached a new steady state). The
dynamic simulations are implemented using the routine ‘ode15s’
in the Matlab.
To evaluate whether IL-6 related parameters are well estimated
(to quantitatively reflect the IL-6 roles in this extended bone
Table 2. The initial values of densities of bone cells and MM
cells in the MM-bone model.
Variables Values Unit References or estimation
OBu/BMSC
1 3.2761026 pM [21]; [76];
OBp
2 7.6761024 pM estimated;
OBa
3 6.3961024 pM [77]; [78];
OCp
4 1.2861023 pM [8];
OCa
5 1.0761024 pM [77]; [78];
MM6 3.2661021 pM [79]; [57];
Note 1: BMSC is 1/2.56105 of total bone marrow cells in adults [21]; the
estimated number of total cells in leg bone marrow is 4.461011 (#) (http://
bloodguys.com/blood-education); the volume of bone marrow in leg is 8.6% of
total bone marrow volume [76]; By assuming that cells in bone marrow are
evenly distributed in different bone types, the number of BMSC in adults is
2.056107 (#) ( = 4.461011/8.6%/2.56105). Given that MM is generally occurred
in the elder people and BMSC percentage in bone marrow decreases to
1/26106 in elder people aged 80 [21], the estimated BMSC number is corrected
to J of the number in adults, namely 5.126106 (#).
Note 2: It is assumed to be 1.2-fold greater than the number of active
osteoblasts (OBa).
Note 3: There are 1,26106 BMU [77] in the total body while there are about
102,103 active osteoblasts (OBa) per BMU [78]. Hence, we estimate OBa
numbers as 16109 (#).
Note 4: Active osteoclasts (OCa) includes 9 nuclei [8] because they are fused by
osteoclast precursors (OCp) differentiated cells. By assuming that OCp is 12-fold
of OCa, The estimated OCp number is 2610
9 (#).
Note 5: There are about 10,102 active osteoclasts (OCa) per BMU [78]. Hence,
we estimate OCa number as 1.67610
8 (#).
Note 6: Synthesis rate of M-protein by MM cells is 0.5,1.2610211 g/day/MM
cell; the half-life of M-protein is 11.6,17 days [79]; the volume of total blood in
the adult is 5L; the diagnosis of MM is required the concentration of M-protein
is greater than 30 g/L [57]. As a result, the estimated MM cell number at the
diagnosis is 5.161011 (#) ( = 30656 (log(2)/17)/1.2610211).
Note 7: All the estimated cell numbers (#) are based on the total human body.
They are converted into density (pM) by divided by Avogadro number
(6.0261023 #/mol) and the volume of total bone marrow, which is estimated
2.6L because the estimated mass of total bone marrow is 2.6 kg (http://en.
wikipedia.org/wiki/Bone_marrow) and the marrow density is assumed to be
close to water.
doi:10.1371/journal.pone.0027494.t002
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model), ratios of pIL6act,RANKL and p
PTH
act,RANKL to (p
IL6
act,RANKL
zpPTHact,RANKL)=2 is calculated respectively. If IL-6 and PTH
equally contribute to RANKL production, both ratios are equal to
1. If IL-6 dominantly contributes to RANKL production, the ratio
pIL6act,RANKL=((p
IL6
act,RANKLzp
PTH
act,RANKL)=2) is greater than 1 while
the ratio pPTHact,RANKL=((p
IL6
act,RANKLzp
PTH
act,RANKL)=2) is lower than 1.
On the contrary, if PTH dominates the contribution to RANKL
production, the ratio pPTHact,RANKL=((p
IL6
act,RANKLzp
PTH
act,RANKL)=2)
is greater than 1, while the ratio pIL6act,RANKL=((p
IL6
act,RANKLz
pPTHact,RANKL)=2) is lower than 1. Based on the ratios, the
quantitative roles of IL-6 in RANKL production and impacts of
IL-6 on the bone microenvironment may be assessed.
The outcomes of the perturbation test series are summarized in
Table 4. In all perturbation tests, bone cells or signaling molecules
quickly reach a new steady state following perturbations and
quickly recover to the original steady state after the perturbations
are removed, which is consistent with the response behavior in the
Pivonka et al. model [1,18]. In terms of changes of bone volume,
the modified model fully aligns with the Pivonka et al. model
[1,18] for all test perturbations. It is worth noting that bone
volume depends on the history of the bone cell populations and so
bone volume reaches a new value after removing perturbations
rather than returning to the original value. All these observations
demonstrate that the new extended bone model incorporating the
new IL-6 related control functions behaves essentially identically
with the Pivonka et al. model [1,18].
At the steady state, the ratio pIL6act,RANKL=((p
IL6
act,RANKLz
pPTHact,RANKL)=2) and p
PTH
act,RANKL=((p
IL6
act,RANKLzp
PTH
act,RANKL)=2) are
found to be 0.4 and 1.6 respectively, indicating the IL-6
contribution to RANKL production is not dominant in the case
of normal bone physiology. This has been achieved through
appropriate model calibration. In all perturbation cases (except for
adding IL-6 perturbation), the IL-6 concentration is not
significantly changed and its contribution to RANKL production
is not significantly increased under normal bone conditions. For
example, when PTH is added at a rate of 1000 pM/day,
concentration of PTH, IL-6 and RANKL increase 2-fold, 1.6-fold
and 3-fold respectively (Figure 4e), while the ratio pPTHact,RANKL=
((pIL6act,RANKLzp
PTH
act,RANKL)=2) increases with a simultaneous de-
creased ratio pIL6act,RANKL=((p
IL6
act,RANKLzp
PTH
act,RANKL)=2) (Figure 4f).
This indicates that TGF-b activation does not induce a substantial
increase in IL-6 production in the extended bone model. In other
words, under normal bone conditions, IL-6 does not make a
dominant contribution to RANKL production.
When IL-6 is injected at a rate of 10 pM/day, IL-6
concentration increases eight-fold while RANKL concentration
increases two-fold (Figure 4c), leading to increase in osteoclast
bone cell densities and a decrease in bone volume (see Figure
4a-b). In addition, the ratio pIL6act,RANKL=((p
IL6
act,RANKLzp
PTH
act,RANKL)
=2) increases from 0.4 to 1.4 while the ratio pPTHact,RANKL=
((pIL6act,RANKLzp
PTH
act,RANKL)=2) decreases from 1.6 to 0.6 (Figure
4d), indicating the relative contribution of IL-6 to RANKL
production is dominant. The IL-6 perturbation analysis demon-
strates that substantial increase in IL-6 is able to produce
significant impacts on the RANKL production and so has a
strong influence on the bone microenvironment.
These results show that the new extended bone model has been
carefully calibrated such that under normal conditions, IL-6 only
does not play a dominant role in bone physiology because of its
moderate regulation of RANKL production. However, if some
mechanism or mechanisms trigger a significant increase in IL-6 in
the bone microenvironment, the IL-6 contribution to RANKL
production can become dominant, inducing significant increase in
RANKL concentration (and consequent increase in densities of
osteoclastic bone cells and bone resorption). Therefore, the
Pivonka et al. model [1] has been suitably extended to take into
account the actions of IL-6 in normal bone physiology in
preparation for modeling MM disease states.
3.2 MM-bone model
3.2.1 Formulation of governing equations. In the
presence of MM cells in the bone environment, MM cells
proliferate due to stimulation by IL-6, MM-BMSC adhesion and
other events, and die due to T-cell interactions and other actions.
The population of MM cells is seen to increase in an S-shape
fashion in a few biological experiments [53,54]. In terms of
mathematical modeling, a logistic function is widely used to model
the S-shape increase in tumor cells [55]. Consequently the
Table 3. The parameter values in the (MM-free) normal bone
model.
Parameters Values Unit References or estimation
DOBu 2.94e+2 /day estimated;
DOBp 3.57e-1 /day estimated;
AOBa 3e-1 /day [1];
DOCp 2e-1 /day estimated;
AOCa 1.2 /day [1];
KM,TGFb,act 4.28e-4 pM [1];
KM,TGFb,rep 2.49e-4 pM [1];
KM,PTH,act 2.09e+2 pM [1];
KM,PTH,rep 2.21e-1 pM [1];
KM,TGFb,IL6,act 2.9e-3 pM estimated;
KM,IL6,RANKL,act 8.8 pM estimated;
KM,RANKL,act 4.79e+1 pM [1];
a 1 pM/% [1];
DTGFb 2e+2 /day [80];
bPTH 9.74e+2 pM/day [81];
DPTH 3.84e+2 /day [81];
bIL6 1.2e+7 /day [36]; [24];
DIL6 4.99e+1 /day [82];
IL6max
1 8.04e-1 pM [75];
bOPG 3.42e+6 /day estimated;
DOPG 4.16 /day [83];
OPGmax
2 7.98e+2 pM [69];
bRANKL 3.37e+5 /day estimated;
DRANKL 4.16 /day [83];
RRANKL 3e+6 - [1];
RANK 1.28e+1 pM [1];
KA,OPG 5.68e-2 /pM [84];
KA,RANK 7.19e-2 /pM [84];
kres 2e+2 %/(pM*day) [18];
kform 3.34e+1 %/(pM*day) estimated;
Note 1: It is assumed to be 30-fold greater than IL-6 concentration at steady
state.
Note 2: It is assumed to be 20-fold greater than OPG concentration at steady
state.
doi:10.1371/journal.pone.0027494.t003
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population growth of MM cells is modeled here using a logistic
function. By assuming the apoptosis of MM cells is a first-order
process, with the rate of the apoptosis proportional to the density
of MM cells [56], the dynamics of MM-cell population satisfies the
following equations:
dMM
dt
~(PMM :p
ligands
MM zPMM,other)
:MM:(1{
MM
MMmax
)
{AMM :MM
ð15Þ
pligandsMM ~p
IL6
act,MMzp
VCAM1
act,MM{p
IL6
act,MM
:pVCAM1act,MM ð16Þ
pIL6act,MM~
IL6
IL6zKM,IL6,MM,act
ð17Þ
pVCAM1act,MM~
1
1z
(1zVLA4:KA,VCAM1):KM,VCAM1,MM,act
VCAM1tot
ð18Þ
where, PMM is the proliferation of MM cells controlled by IL-6 and
MM-BMSC adhesion. PMM,other is the proliferation of MM cells
controlled by other events (e.g., IGF-1 rather than arising from IL-
6 and MM-BMSC adhesion). AMM is the apoptosis of MM cells.
pligandsMM is the enhanced (c~{1) ‘activator’ function in response to
simultaneous MM-BMSC adhesion and IL-6 stimulation (as
defined by the Eq.(3)). pIL6act,MM and p
VCAM1
act,MM are the ‘activator’
functions in response to IL-6 and MM-BMSC adhesion
stimulation separately. KM,VCAM1,MM,act and KM,IL6,MM,act are the
half-maximal concentration of VLA-4 and IL-6 on facilitating
MM-cell proliferation. KA,VCAM1 is the association rate constant for
VLA-4 binding to VCAM-1. VCAM1tot is the total concentration
of VCAM-1. The details to derive Eq.(18) are described in
Supporting Information S1.
The membrane bound VLA-4 concentrations at steady-state are
calculated in much the same way as RANKL concentrations (see
equation (31)-(36) in Pivonka et al. [1]), via:
VLA4eff~R
VLA4:MM ð19Þ
VLA4~
PVLA4,dzbVLA4
:MM
(1zKA,VCAM1:VCAM1tot):(
bVLA4
RVLA4
zDVLA4)
ð20Þ
where VLA4eff represents the ‘effective carrying capacity’ on the
surface of MM cells, which sets the maximum concentration of
VLA-4. PVLA4,d is the external production rate of VLA-4 with the
unit of pM:day{1. KA,VCAM1 is the association rate constant for
VLA-4 binding to VCAM-1. RVLA4 is the maximal number of
VLA-4 that can be expressed on the surface of MM cells. bVLA4 is
Table 4. Outcomes of perturbations on the (MM-free) normal bone model.
Perturbations
Bone cells
(OBp, OBa, OCa) Bone volume
Molecules
(OPG, RANKL, IL-6)
OBp q
Adding 8e-5 pM/day
q q, to new value;
above normal;
q
OBa q
Adding 6e-5 pM/day
OBa q but OBp and OCa Q q, to new value;
above normal;
OPG q but RANKL and IL-6 Q
OCa q
Adding 1e-5 pM/day
q Q then q to
new value;
below normal;
q
OBp Q
Removing 3e-5 pM/day
Q Q, to new value;
below normal;
Q
OBa Q
Removing 2e-5 pM/day
OBa Q but OBp and OCa q Q, to new value;
below normal;
OPG Q but RANKL and IL-6 q
OCa Q
Removing 3e-6 pM/day
Q q then Q to new value;
above normal;
Q
PTH q
Adding 1e+3 pM/day
q Q then q to
new value;
below normal;
RANKL and IL-6 q but OPG Q
OPG q
Adding 2e+2 pM/day
Q q then Q to new value;
above normal;
OPG q but RANKL and IL-6 Q
RANKL q
Adding 3e+2 pM/day
q Q then q to
new value;
below normal;
q
IL-6 q
Adding 10 pM/day
q Q then q to
new value;
below normal;
q
OPG Q
Removing 5e+1 pM/day
q Q then q to
new value;
below normal;
OPG Q but RANKL and IL-6 q
Note 1: All perturbation responses in (MM-free) bone model (except IL-6 perturbation response) are qualitatively consistent with those of Pivonka et al. model [1,18].
Note 2: This table summarizes transient changes of state variables (i.e. densities of bone cells and molecule concentrations) after adding perturbations, while it
summarizes transient changes in bone volume after adding perturbations together with the new state of bone volume reached after removing perturbations.
doi:10.1371/journal.pone.0027494.t004
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the production of VLA-4 by MM with the unit of day{1. DVLA4 is
the degradation of VLA-4. VCAM1tot is the total concentration of
VCAM-1.
In the presence of MM cells, IL-6 production is stimulated not
only by TGF-b but also by MM-BMSC adhesion. To account for
this, the calculation of IL-6 concentration in updated form (from
Eq.(9)) is as follows:
IL6~
PIL6,dzbIL6
:OBu:p
ligands
IL6
bIL6
:OBu:p
ligands
IL6
IL6max
zDIL6
ð21Þ
pligandsIL6 ~p
TGFb
act,IL6zp
VLA4
act,IL6zc
:pTGFbact,IL6
:pVLA4act,IL6 ð22Þ
pVLA4act,IL6~
VLA4
VLA4zKM,VLA4,IL6,act
ð23Þ
where, pligandsIL6 is a synergistic ‘activator’ function in response to
VLA-4 and simultaneous TGF-b stimulation (its calculation is
defined by Eq.(3)). pTGFbact,IL6 and p
VLA4
act,IL6 are ‘activator’ functions in
response to TGF-b and MM-BMSC adhesion stimulation.
KM,VLA4,IL6,act and KM,TGFb,IL6,act are the half-maximal concentra-
tions of VLA-4 and TGF-b respectively, when promoting the
production of IL-6.
By assuming the internalization and degradation of OPG by
MM cells is proportional to OPG concentrations and the density
of MM cells, the calculations of OPG concentration is updated
from [1] as follows:
OPG~
POPG,dzbOPG
:OBa:p
PTH
rep,OBa
bOPG
:OBa:p
PTH
rep,OBa
OPGmax
zDOPGzDOPG,MM :MM
ð24Þ
where, POPG,d is the external production rate of OPG with the unit
of pM:day{1. bOPG is the endogenous production of OPG by
active osteoblasts with the unit of day{1. OPGmax is the maximal
concentration of OPG produced by active osteoblasts. DOPG is the
degradation of OPG. DOPG,MM is the degradation of OPG by MM
cells. pPTHrep,OBa is the ‘repressor’ function, which is the same as that
in [1].
In the presence of MM cells, RANKL is produced not only by
the osteoclast precursors (OBp), but also by the uncommitted
osteoblasts (OBu) as a result of MM-BMSC adhesion. Our
estimations suggest that the number of OBu cells is two orders of
magnitude lower than the number of OBp cells, that is, OBu ,,
OBp (see Table 2). Consequently, RANKL production by OBu cells
is thought to contribute little to the total RANKL concentrations in
the context of MM disease, and so this contribution may be
neglected without significantly influencing MM disease progression.
For this reason, the calculation for the RANKL concentrations in
the presence of MM cells is the same as Eq.(14).
3.2.2 Bifurcation. Eq.(15) represents the balance between a
source term (due to the proliferation of MM cells) and a sink term
(due to the apoptosis of MM cells). The density of MM cells may
increase or decrease depending on parameter values. Clearly, if
the source term is greater than the sink term, MM-cell density
increases, while if source term is smaller than the sink term, MM-
cell density decreases. A dynamic increase in MM-cell density may
suddenly revert to the dynamic decrease in MM-cell density at a
critical condition, and vice versa. In other words, a bifurcation
might occur in the MM cell population equation (Eq.(15)), which is
determined by the critical condition.
PMM :p
ligands
MM zPMM,other{AMM~0:
If PMM :p
ligands
MM zPMM,other{AMM .0, MM-cell density
increases;
If PMM :p
ligands
MM zPMM,other{AMM =0, MM-cell density
remains constant;
If PMM :p
ligands
MM zPMM,other{AMM ,0, MM-cell density
decreases.
In order to ensure an increase in MM-cell density during
simulations of the MM-bone model, the first condition has to be
met. Because PMM,other is assumed to be very small in the model,
the critical condition is mainly determined by the parameters PMM,
AMM and p
ligands
MM . While PMM and AMM are independent of time,
pligandsMM is time dependent because it is a function of the
concentrations of IL-6 and VLA-4, which are time dependent.
At the beginning of simulation, the concentrations of IL-6 and
VLA-4 can be calculated from the steady state of normal bone
model and the initial density of MM cells respectively; and so the
value of pligandsMM is estimated at the beginning of simulation. AMM is
estimated as 261023/day according to the literature; consequent-
ly, PMM must be greater than 2.87610
22/day to meet the first
condition, ensuring MM cells increase from the beginning of
simulation (note that MM cell density may subsequently decrease
if PMM changes during the simulation).
3.2.3 Simulations. In order to simulate the transient
behavior of the MM-bone model following the introduction of
MM cells, the initial state for MM cells needs to be estimated. MM
disease progression is clinically divided into three phases according
to criteria for classification recommended by IMWG [57]: (i)
monoclonal gammopathy of undetermined significance (MGUS);
(ii) so-called ‘smoldering MM’ (or asymptomatic MM); (iii)
malignant MM (or symptomatic MM). Malignant MM is
associated with bone lesions, while MGUS and smoldering MM
does not exhibit bone lesions. Because our primary concern is
MM-induced bone destruction, our simulations are focused on
phase (iii)-malignant MM. Furthermore, malignant MM (phase
(iii)) is further divided into three clinical stages (namely, stages I, II
and III), based on staging system of Durie-Salmon (or some
alternate combination of prognostic factors) [58,59]. The median
survival duration following diagnosis is currently in the range 50–
55 months [60]. As a result, our simulations here start from the
early part of stage I in phase (iii) of MM, and end at the end of
stage III, phase (iii), with this transition occurring over a time
period of about 60 months. For these circumstances, the initial
density of MM cells is estimated as 0.326 pM (see Table 2).
Figure 4. Perturbations of the (MM-free) normal bone model. (a) Bone cells after adding IL-6. (b) Bone volume after adding IL-6. (c) Molecules
after adding IL-6. (d) Ratios of pPTHact,RANKL and p
IL6
act,RANKL to (p
PTH
act,RANKLzp
IL6
act,RANKL)=2 respectively after adding IL-6. (e) Molecules after adding PTH. (f)
Ratios of pPTHact,RANKL and p
IL6
act,RANKL to (p
PTH
act,RANKLzp
IL6
act,RANKL)=2 respectively after adding PTH.
doi:10.1371/journal.pone.0027494.g004
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The parameter values of the MM-bone model are given in
Table 5. These parameters are estimated based on reported values
in the literature, together with best-fitting model estimates from
least-square optimization criteria (i.e. parameters bVLA4, DOPG,MM
and c are optimized using this criteria). It should be noted that
although there are a lot of parameters, the values for most of them
are not obtained by fitting procedures. About 80% of model
parameters are pathophysiology-related and estimated based on
experiments reported in the literature. The optimization criterion
used in this paper is to minimize the errors between simulations
and experiments or clinical observations, that is, to minimize the
following objective function:
J~
Xm
j~1
½ypred{yexpj
n o2
½yexpj
n o2 ð25Þ
Where, the ypred and yexp are normalized simulated values and
corresponding experimental or clinical values respectively, at the
end of simulations. The j represents different variables (specifically,
they refer to MM-cell density, IL-6 concentrations, RANKL
concentrations and OPG concentrations). The values of [ypred]j are
calculated using the routine ‘ode15s’ in the Matlab and the values
of [yexp]j are estimated based on clinical observations (specifically,
MM-cell density is estimated to increase 5-fold, IL-6 concentration
to increase 10-fold, RANKL concentration to increase 4-fold and
OPG concentration to decrease 0.7-fold, at the end of the
simulations (see Table 6)). The optimization process is implement-
ed using the routine ‘patternsearch’ in Matlab.
With the calibrated parameter values (e.g., PMM equals 0.055/
day), transient behavior of bone cells, MM cells and bone volume
are simulated. The code has been checked in accordance with a
comprehensive comparison of the simulation results against
clinical data as reported in the literature (refer Section 3.2.5).
Good agreement has been demonstrated. As cyan dash lines in
Figure 5a-e show, MM cells and bone cells increase quickly and
approach an upper limit after about 4 years, while bone volume
continuously decreases. This curve represents a progressive MM
disease process and approaches an upper limit at about the mean
time for death that is observed clinically. It is worth noting that
bone cells exhibit a sharp increase at the very beginning of
simulations followed by an S-shape increase until the end state.
Because we simulate the MM development in bone marrow by
starting from stage I phase (iii) of MM (initial density of MM cells
is 0.326 pM), this sharp increase is artificial and actually driven by
the accumulated increase in bone cells during the period from the
start of MM until the beginning of stage I phase (iii). After this
sharp increase, the S-shape increase represents increased bone
cells due to the MM disease over the period from stage I phase (iii)
to stage III phase (iii).
Furthermore, as indicated by sensitivity analysis (see following
section) the population growth of MM cells is most dependent on
the proliferation of MM cells (the parameter PMM), and so the
influence of PMM on the MM-cell population growth and MM-
induced bone resorption are considered further. For different PMM
values, different evolutions of MM are observed in the model (see
Figure 5a-e). For example, when PMM equals 0.035/day, MM cells
and bone cells slightly increase and bone volume loss remains
small. This curve indicates that MM is only slightly progressive.
When PMM equals 0.045/day, MM cells, bone cells and bone
volume loss increases more. When PMM equals to 0.065/day, MM
cells and bone cells increase more quickly and reach the upper
limit by about 3 years, while reducing bone volume more
significantly. This curve represents a more rapid progression of
MM than the mean time observed clinically.
Figure 5f shows that the ‘activator’ function for IL-6 production,
simultaneously stimulated by TGF-b and MM-BMSC adhesion,
increases fourteen-fold at the end of simulation, while ‘activator’
function of IL-6 production stimulated by either TGF-b or MM-
BMSC adhesion increase by only two-fold and four-fold
respectively. The ratio of IL-6 production by two ligands
stimulation compared to the sum of each ligand separately is over
Table 5. The parameter values in the MM-bone model.
Parameters Values Unit References or estimation
PMM 5.5e-2 /day estimated;
PMM,other 2e-4 /day estimated;
AMM 2e-3 /day [85];
MMmax 1.98 pM [79];
KM,VCAM1,MM,act 8.07e-2 /pM estimated;
KM,VLA4,IL6,act 3.36e+5 /pM estimated;
KM,IL6,MM,act 1.76 pM estimated;
bVLA4 2.74e+6 /day calibrated;
DVLA4 2 /day estimated;
RVLA4 5.6e+4 - [86];
VCAM1tot 1.92 pM [86];
KA,VCAM1 8.3e-2 /pM [87];
DOPG,MM 4.11 /(pM*day) calibrated;
c -1 (enhanced response) or
2.47e+1 (synergistic response)
- estimated for enhanced response while
calibrated for synergistic response;
Note 1: The external dosing rate PVLA4,d, PIL6,d, POPG,d and PRANKL,d are all set to zero.
doi:10.1371/journal.pone.0027494.t005
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two-fold at the end of simulation, confirming the ‘synergistic’
effects of simultaneous TGF-b and MM-BMSC adhesion
stimulation on the IL-6 production.
Clearly, as can be seen from Figure 5g, the ‘activator’ function
of MM-cell proliferation stimulated by IL-6 increases three-fold at
the end of simulation, while the ‘activator’ function of MM-cell
proliferation simulated by MM-BMSC adhesion decreases to 20%
of its original value However the ‘activator’ function of MM-cell
proliferation simultaneously stimulated by IL-6 and MM-BMSC
adhesion stimulation increase about two-fold at the end of
simulations. This suggests that MM-cell proliferation mainly
results from IL-6 stimulation as the MM disease process
progresses, while MM-BMSC adhesion contributes to a lesser
amount to MM-cell proliferation.
3.2.3 Sensitivity analysis. In order to clarify the impacts of
various parameters on MM disease progression, a sensitivity
analysis is performed to identify critical parameters. The sensitivity
is defined as the relative change of an output variable vi to the
relative change in an input variable pj at the relevant time point,
The sensitivity may be calculated as [61]:
sij~(Lvi=vi)=(Lpj=pj) ð26Þ
Given that the sensitivity estimate found from Eq.(26) is
evaluated at a single time, while we are concerned with temporal
changes of output variables over a period of 60 months, we extend
this concept using the time integral
Ð jsij(t)jstarting from the
beginning of the simulation and finishing at the endpoint of the
simulation. The greater the integral, the greater the time averaged
sensitivity between a specific output variable and a specific input
variable.
Figure 6 shows the outcomes of such a sensitivity analysis. It is
apparent that the density of MM cells is most sensitive to PMM,
bIL6, AMM, DOCp and AOCa while bone volume is most sensitive to
AOBa, DOBu, DOCp and AOCa. Because parameters PMM, bIL6 and
AMM are directly associated with MM-cell density they are
regarded as MM-related parameters. Likewise, parameters AOBa,
DOBu, DOCp and AOCa are directly associated with bone-cell density
and bone volume and so they are regarded as bone-related
parameters (bIL6 may also be regarded as bone-related parameter
due to the dual roles of IL-6). More specifically, AOBa, and DOBu are
osteoblast-related parameters whereas DOCp and AOCa are osteo-
clast-related parameters. Outcomes of the sensitivity analysis
suggest that MM-cell density are most sensitive to MM-related
group of parameters, and next most sensitive group are the
osteoclast-related parameters, while bone volume is most sensitive
to osteoblast-related group of parameters and next most sensitive
to osteoclast-related parameters. Bone volume seems least sensitive
to MM-related parameters while MM-cell density seems least
sensitive to osteoblast-related parameters. These outcomes appear
to be consistent with experimental or clinical observations. For
example, anti-catabolic agents (e.g., an inhibitor of osteoclast
activity or a specific inhibitor of RANKL) halt MM-induced bone
resorption and result in inhibition of MM cell proliferation and
survival [62,63]. However, osteolytic lesions may still progress
even if patients with MM respond to anti-MM therapy [64,65].
3.2.3 Detailed comparisons of model outcomes and
clinical observations. The main goal of this paper is to
clarify whether this proposed MM-bone model appropriately
reflects clinical data on MM disease progression in bone marrow.
The observed major clinical features of MM disease include: the
increased bone resorption markers (i.e., N-terminal telopeptides
of type I collagen, NTX) and bone formation marker (i.e.,
bone-specific alkaline phosphotase, bALP) [66], indicating an
increase in the number of osteoclasts and osteoblasts as a result of
increased RANKL and decreased OPG concentrations. The
elevated osteoclast and osteoblast activities lead to increased bone
turnover and reduced bone volume [66]. Malignant plasma cells
(MM cells) in bone marrow secrete paraprotein (i.e., Bence-Jones
proteins) and prognostic indicators of MM disease (e.g., IL-6),
which increase as MM disease progresses [66-68].
Table 6. Comparisons of the MM-bone model outcomes under the condition of PMM= 0.055/day with experimental observations.
Stage I/II Stage III
experiments simulations experiments simulations
RANKL 1.62-fold [70] 1.75-fold 2.65-fold [69];
2.26-fold [70];
13.5-fold [71];
15.67-fold [72];
4.35-fold
IL-6 2.6-fold/4.22-fold [75] 3.55-fold 9.79-fold [75] 10-fold
OPG Q [69];
q [88]1
Q 0.71-fold [73];
0.73-fold [38];
0.82-fold [74];
0.59-fold [69]
0.69-fold
OBa q [67,68,89] q q [67,68,89] q
OCa q [67,68,89] q q [67,68,89] q
Bone turnover q [67,68,89] q q [67,68,89] q
Bone volume Q [67] Q Q [67] Q
MM cells 3-fold [67] q Up to 6-fold [67] 4.48-fold
Note 1: Clinically, it is observed that serum OPG concentrations decrease at the early stage of MM disease [69], while it is recently suggested that serum OPG
concentrations increase compared with healthy controls [88]. The exact reasons to cause the different observations are still not known. Possibly, OPG is produced by
various skeletal and extra-skeletal tissues [90], leading to serum OPG concentrations do not reflect its availability in the bone microenvironment [88].
Note 2: All the ratios of experiments are obtained by comparing with healthy controls, whereas all the ratios of simulations are obtained by comparing with steady state
of the normal bone model.
doi:10.1371/journal.pone.0027494.t006
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Further, relative to normal healthy subjects, serum sRANKL
(soluble RANKL) concentrations increase about one and a half
fold in patients with stage I or stage II MM. Serum RANKL
concentrations increase more variably later in the course of the
disease. For example, relative to normal healthy subjects, serum
RANKL concentrations are reported to increase 2.65-fold [69],
2.26-fold [70], 13.5-fold [71], and 15.67-fold [72] in patients with
stage III MM. Relative to healthy controls, serum OPG
concentrations have recently been reported to increase about
one and half fold in patients with early stage MM [70], however in
late stage MM, serum OPG concentrations have been reported to
decrease 29% [73], 27% [38], 18% [74] and 41% [69]. Relative to
healthy controls, serum IL-6 concentrations have been reported to
increase 2.57-fold, 4.22-fold and 9.79-fold in MM patients at
stages I, II and III respectively [75]. For patients with MM,
measureable concentrations of IL-6 and sIL-6R are found in both
marrow fluid and serum patients, and both fluids show similar
increases in concentration [66]. The number of malignant plasma
cells in bone marrow can account for up to 65% of the total
number of cells in the bone marrow [67]. This is over six times
higher than the clinical diagnosis criteria for MM with MM cells
comprising 10% of the total number of cells. All these clinical
observations are summarized in Table 6.
Most importantly, comparisons between the model outcomes
and the above-mentioned clinical observations demonstrate that
our simulation qualitatively and quantitatively agrees with these
clinical observations. As summarized in Table 6, at the early stage
I phase of MM, simulated RANKL and IL-6 concentration
increase about 1.75-fold and 3.55-fold respectively, while clinical
observations indicate that RANKL and IL-6 concentration
increase about 1.62-fold and 2.6-fold respectively [70,75]. For
the MM example with PMM = 0.055/day, at the endpoint of
simulation (corresponding to later stage III phase of MM),
simulated concentrations of OPG, RANKL and IL-6 and MM-
cell density increase 0.69-fold, 4.35-fold, 10-fold and 4.48-fold
respectively, while clinical observations suggest that concentrations
of OPG, RANKL and IL-6 and MM-cell density increase
approximately 0.7-fold [38,73], 4-fold [69,70], 10-fold [75] and
5-fold respectively (Figure 5d). The simulations also indicate that
the density of osteoblast precursors (OBp), active osteoblasts (OBa)
and active osteoclasts (OCa) increase 2.14-fold, 1.65-fold and 1.97-
fold respectively (Figure 5a-c) while bone volume decreases to 91%
at the end of year-5 (Figure 5e), which are qualitatively consistent
with clinical observations [67]. The synergistic effect of TGF-b
and MM-BMSC adhesion on IL-6 production by BMSCs is also
observed. The simulated ratio of IL-6 production by two ligands
stimulation compared to the sum of each ligand separately is
between 1.48-fold and 2.19-fold, while the reported experimental
ratio is between 1.45-fold and 2-fold [35].
The quantitative and qualitative agreements between our
simulations and clinical observations suggest that this proposed
MM-bone model is able to capture some of the major features of
the MM disease progression and so within the limitations of the
model, appropriately reflect the MM disease progression in bone
marrow.
Discussion
4.1 The relative importance of regulation by the positive
feedback cycles
There are two positive feedback cycles identified in our MM-
bone model (see Figure 2). Based on the similarity of the clinically
Figure 5. Simulations of the MM-bonemodel for various PMM Values. (a) OBp. (b) OBa. (c) OCa. (d) MM cells. (e) Bone volume. (f) The ‘activator’
function for IL-6 production (PMM= 0.055/day). (g) The ‘activator’ function for the proliferation of MM cells (PMM=0.055/day).
doi:10.1371/journal.pone.0027494.g005
Figure 6. Outcomes of relative sensitivity analysis. 1-DOBu; 2-DOBp; 3-AOBa; 4-DOCp; 5-AOCa; 6-bIL6; 7-bOPG; 8-bRANKL; 9-PMM; 10-PMM,other; 11-AMM;
12-bVLA4; 13-DOPG,MM; 14-c.
doi:10.1371/journal.pone.0027494.g006
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observed normalized increase in MM cells and the normalized
decrease in bone volume and the model results (see Figure 5d-e),
this suggests that the two feedback cycles included in the model are
sufficient to jointly drive the disease interaction between MM cells
and the bone microenvironment. However, the relative impor-
tance of the two positive feedback cycles is not yet clear. This issue
can be addressed by performing a quantitative analysis on the
positive feedback cycles.
Our quantitative analysis on the relative importance of the
positive feedback cycles is based on comparing changes of
variables when both positive feedback cycles are intact, with
model outcomes when either one or other, or both, of the positive
feedback cycles are disabled (i.e. blocked). The density of MM cells
and the bone volume are suitable variables to track for evaluating
the significance of the two positive feedback cycles on MM disease
progression. The dynamic changes of MM-cell density and bone
volume during MM disease progression may be quantified by
calculating the ‘area under the curve’ (AUC), which is defined as
the time integral of the change in the variable from beginning of
the simulation to the end of the simulation. We propose that if the
total change of MM-cell density is reduced by ten to fifty percent,
or total change of bone volume loss is reduced by ten to fifty
percent, when either one of the positive feedback cycles is blocked,
then this feedback cycle is deemed ‘significant’ with respect to
bone volume or MM-cell density.
The expression ‘vicious cycle’ is commonly used in the
biological/cancer literature to identify positive feedback loops
between the cancer cells and their microenvironment; however it
is not usually given a quantitative definition. Here we propose that
if blocking a positive feedback cycle is effective in more than
halving the MM-cell density (i.e. greater than a fifty percent
reduction) or more than halving the bone loss (i.e. greater than fifty
percent reduction) or doing so to both, then we say this positive
feedback cycle is a ‘vicious cycle’. This definition at least accords
with the original intention of use of this expression by Mundy [13].
We investigated five cases where the two positive feedback
cycles are blocked at different points in their cycle, namely (i)
positive feedback cycle A is blocked at the point of IL-6 interaction
with osteoblast precursors, (ii) positive feedback cycle B is blocked
at the point of IL-6 interaction with MM cells, (iii) positive
feedback cycle A and B are simultaneously blocked for IL-6 at the
point of IL-6 production, (iv) an additional contribution to positive
feedback cycle A is blocked at the point of OPG degradation by
MM cells, and (v) an additional contribution to positive feedback
cycle B is blocked at the point of MM-BMSC adhesion-stimulated
MM cell proliferation. The precise blocking points of all these
cases are illustrated in Figure 7.
Figure 8a-b show dynamic changes of bone volume and MM-
cell density corresponding to each of the above-mentioned cases. It
is noted here that PMM is selected as 0.055/day for the purpose of
clearly displaying the results, but in fact, the conclusions for this
value hold true for other values of PMM. A marked reduction of
bone volume loss is observed in the first and the second case, while
there is a slight increase in bone volume observed in the third case.
Slightly less density of MM cells is observed in the first case
whereas a marked decrease in MM-cell density is observed in the
Figure 7. Schematic showing blocks in the MM-bone positive feedback cycles at specific points in the MM-bone model.
doi:10.1371/journal.pone.0027494.g007
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second and the third case (curves of the second and the third case
are overlapped in the Figure 8b).
These changes suggest to us that MM cell population growth
and bone volume loss are reversed when these two positive
feedback cycles are simultaneously blocked, while they are partly
inhibited when only one of the positive feedback cycles is blocked.
Furthermore as shown in Table 7, the AUC of bone volume when
the positive feedback cycle A and B are blocked compared to that
when both positive feedback cycles are intact, expressed as a
percentage is 6.74% and 31.06% respectively. The AUC of MM-
cell density when the positive feedback cycle A is blocked
compared to that when both positive feedback cycles are intact,
expressed as a percentage is 79.77%. Based on these quantitative
results for bone volume and MM-cell density changes and our
definition, IL-6 stimulated RANKL production by osteoblast
precursors is deemed to be significant with respect to bone volume,
and IL-6 stimulated MM cell proliferation is deemed significant
with respect to both bone volume and MM-cell density.
Additionally, both positive feedback cycles would qualify as
‘vicious cycles’ with respect to bone volume changes. In contrast,
positive feedback cycle A is deemed not to be a ‘vicious cycle’ with
respect to MM-cell density, while positive feedback cycle B is
deemed to be a ‘vicious cycle’ with respect to MM-cell density.
In addition, a marked reduction of bone volume loss is observed
in the fourth case, while slightly lesser density of MM cells is
observed in the fourth case. As shown in Table 7, the AUC of
bone volume in the fourth case compared to that when positive
feedback cycles are intact, expressed as a percentage is 38.47%,
while the AUC of MM-cell density in the fourth case compared to
that when positive feedback cycles are intact, expressed as a
percentage is 89.76%. These changes suggest to us that
degradation of OPG by MM cells has a very significant impact
on bone volume loss, while it almost has no impact on MM cell
population growth. In terms of the fifth case, both a slight
reduction of bone volume loss and slightly lesser density of MM
cells are observed. The percentage of AUC of bone volume and
the percentage of AUC of MM-cell density in the fifth case,
compared to those when both positive feedback cycles are intact
are 78.35% and 79.4% respectively (see Table 7), indicating that
MM-BMSC adhesion-stimulated MM cell proliferation has
neither a significant impact on the bone volume loss nor on
MM cell population growth.
From these analyses, a picture of the dominant processes
emerges. In the presence of MM cells, MM-BMSC adhesion and
TGF-b induce ‘synergistic’ production of IL-6 by BMSCs. The
substantially increased IL-6 concentration stimulates proliferation
Figure 8. Model outputs after blocking positive feedback cycles in the MM-bone model. (a) Bone volume after blocking positive feedback
cycles at specified points. (b) The density of MM cells after blocking positive feedback cycles at specified points. Case 1 Positive feedback cycle A is
blocked at the point of interaction of IL-6 and osteoblast precursors. Case 2 Positive feedback cycle B is blocked at the point of interaction between
IL-6 and MM cells. Case 3 Positive feedback cycles A and B are simultaneously blocked at the point of IL-6 production by BMSC. Case 4 Positive
feedback cycle A is blocked at the point of OPG degradation by MM cells. Case 5 Positive feedback cycle B is blocked at the point of MM-BMSC
adhesion-stimulated MM-cell proliferation.
doi:10.1371/journal.pone.0027494.g008
Table 7. The percentages of AUC of bone volume and MM-cell density when positive feedback cycles are blocked to those when
these cycles are intact.
Case 1 Case 2 Case 3 Case 4 Case5
Percentage of AUC of bone volume 6.74% 31.06% q 38.47% 78.35%
Percentage of AUC of MM-cell density 79.77% Q Q 89.76% 79.4%
Note: case 1: Positive feedback cycle A is blocked at regulation mechanism between IL-6 and osteoblast precursors; case 2: Positive feedback cycle B is blocked at
regulation mechanism between IL-6 and MM cells; case 3: Positive feedback cycle A and B are simultaneously blocked at regulation mechanism of IL-6 production; Case
4: additional pathway to positive feedback cycle A is blocked at regulation mechanism of OPG degradation by MM cells. Case5: additional pathway to positive feedback
cycle B is blocked at regulation mechanism of MM-BMSC adhesion-stimulated MM-cell proliferation.
doi:10.1371/journal.pone.0027494.t007
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of MM cells leading to enhanced MM-BMSC adhesion and more
degradation of OPG. On the other hand, increased RANKL
production by osteoblast precursors together with decreased OPG
concentration result in more bone resorption and more TGF-b
released from bone matrix. The dominant processes in the two
positive feedback cycles are highlighted by the red arrows in
Figure 9. These dominant processes suggest potential drug targets
to achieve different therapeutic objectives. For example, targeting
IL-6-stimulated RANKL production by osteoblast precursors can
reduce bone loss and so improve MM-induced bone lesions, while
targeting IL-6-stimulated MM cell proliferation can reduce MM
tumor burden and contribute to improving MM-induced bone
lesions.
Conclusion
In this paper, we have developed a computational model
describing interactions between multiple myeloma and bone. This
computational model is based on the previous bone remodeling
model of Pivonka et al. [1], and explicitly considers IL-6 and MM-
BMSC adhesion related pathways. Inclusion of these new
pathways leads to the formation of two positive feedback cycles
in this model. The parameters of this model are estimated based
on reported values in the literature, and when required, best-fit
parameter estimates are made using a least-square optimization
criterion. Using this approach, the progression of MM disease is
simulated numerically. Our model simulations are qualitatively
and quantitatively consistent with known clinical observations for
both normal bone physiology and for MM disease progression.
This model suggests that the two MM-bone positive feedback
cycles employed in this computational model are sufficient to
jointly drive MM disease progression.
Analysis of the model behavior resulted in the clarification of the
relative importance of the two positive feedback cycles, and
identified the dominant influences within the feedback cycles. The
dominant influences contributing to the feedback cycles suggest
possible drug targets, which are different for different clinical
objectives.
It is hoped that this computational model describing the
interactions between multiple myeloma and bone can be improved
over time, and eventually applied as a modeling platform for
analyzing the relative efficacy of various therapeutic interventions.
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